KLK3 and posterior cortical atrophy: While prostate specific antigen (PSA)-screening has decreased PCa mortality rates in the U.S., it has done so at the cost of detecting early stage/grade PCa that might not affect a patient's life if untreated (overdiagnosis) [1]–[4].